These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8212072)

  • 1. Preliminary assessment of luteolin as an affinity ligand for type II estrogen--binding sites in rat uterine nuclear extracts.
    Markaverich BM; Gregory RR
    Steroids; 1993 Jun; 58(6):268-74. PubMed ID: 8212072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purification and characterization of nuclear type II [(3)H]estradiol binding sites from the rat uterus: covalent labeling with [(3)H]luteolin.
    Markaverich BM; Shoulars K; Brown MA
    Steroids; 2001 Sep; 66(9):707-19. PubMed ID: 11546559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial purification and characterization of methyl-p-hydroxyphenyllactate esterase in rat uterine cytosol.
    Maybruck WM; Markaverich BM
    Steroids; 1997 Mar; 62(3):321-30. PubMed ID: 9071742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition.
    Markaverich BM; Roberts RR; Alejandro MA; Johnson GA; Middleditch BS; Clark JH
    J Steroid Biochem; 1988; 30(1-6):71-8. PubMed ID: 3386279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear type II [3H]estradiol binding sites: a histone H3-H4 complex.
    Shoulars K; Rodrigues MA; Crowley JR; Turk J; Thompson T; Markaverich BM
    J Steroid Biochem Mol Biol; 2005 Jun; 96(1):19-30. PubMed ID: 15878266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary characterization and partial purification of rat uterine nuclear type II Binding sites.
    Markaverich BM; Gregory RR
    Biochem Biophys Res Commun; 1991 Jun; 177(3):1283-90. PubMed ID: 2059216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of nuclear type II [(3)H]estradiol binding sites as histone H4.
    Shoulars K; Brown T; Alejandro MA; Crowley J; Markaverich BM
    Biochem Biophys Res Commun; 2002 Sep; 296(5):1083-90. PubMed ID: 12207884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear binding of the estrogen receptor: heterogeneity of sites and uterotropic response.
    Clark JH; Markaverich B; Upchurch S; Eriksson H; Hardin JW
    Adv Exp Med Biol; 1979; 117():17-46. PubMed ID: 474276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary characterization of an endogenous inhibitor of [3H]estradiol binding in rat uterine nuclei.
    Markaverich BM; Roberts RR; Finney RW; Clark JH
    J Biol Chem; 1983 Oct; 258(19):11663-71. PubMed ID: 6619136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An improved method for the quantification and recovery of rat uterine nuclear type II [3H]estradiol binding sites immobilized on a glass fiber matrix.
    Densmore CL; Tiller AA; Gregory RR; Schauweker TH; Webb B; Markaverich BM
    Steroids; 1995 Feb; 60(2):214-9. PubMed ID: 7618188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of nuclear estrogen-binding sites in the rat uterus: a simple method for the quantitation of type I and type II sites by [3H]estradiol exchange.
    Markaverich BM; Williams M; Upchurch S; Clark JH
    Endocrinology; 1981 Jul; 109(1):62-9. PubMed ID: 7238414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo inhibition of nuclear type II estrogen binding sites in the dorsolateral prostate of noble rats.
    Ho SM; Viccione T; Yu M
    J Steroid Biochem Mol Biol; 1993 Oct; 46(4):489-95. PubMed ID: 8217879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation.
    Markaverich BM; Alejandro MA
    Int J Oncol; 1998 May; 12(5):1127-35. PubMed ID: 9538139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth.
    Markaverich BM; Gregory RR; Alejandro M; Kittrell FS; Medina D; Clark JH; Varma M; Varma RS
    Cancer Res; 1990 Mar; 50(5):1470-8. PubMed ID: 2302712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones.
    Markaverich BM; Schauweker TH; Gregory RR; Varma M; Kittrell FS; Medina D; Varma RS
    Cancer Res; 1992 May; 52(9):2482-8. PubMed ID: 1568218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells.
    Reiner GC; Katzenellenbogen BS; Bindal RD; Katzenellenbogen JA
    Cancer Res; 1984 Jun; 44(6):2302-8. PubMed ID: 6547074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reconstitution of the type II [3H]estradiol binding site with recombinant histone H4.
    Shoulars K; Rodriguez MA; Crowley J; Turk J; Thompson T; Markaverich BM
    J Steroid Biochem Mol Biol; 2006 Apr; 99(1):1-8. PubMed ID: 16621524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of the calf uterine estrogen receptor with acceptor sites in heterologous chicken target cell nuclei.
    de Boer W; Snippe L; Ab G; Gruber M
    J Steroid Biochem; 1986 Apr; 24(4):825-33. PubMed ID: 3702460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro effects of cytosolic inhibitor and opiates on the binding of [3H]oestradiol to nuclear type II binding sites of rat uterus and hypothalamus.
    Garai J; Vértes M; Kovács S
    J Steroid Biochem; 1989 Mar; 32(3):433-8. PubMed ID: 2704239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of [3H]estradiol binding sites in the rat prostate: properties and distribution of type I and type II sites.
    Yu M; Cates J; Leav I; Ho SM
    J Steroid Biochem; 1989 Sep; 33(3):449-57. PubMed ID: 2779236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.